Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEACO: Oxaliplatin, Docetaxel, and Bevacizumab in Ovarian Cancer
NCT00296816Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2006
- Primary completion
- Aug 2011
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, oxaliplatin in ovarian cancer, primary peritoneal carcinoma (PPC), fallopian tube carcinoma (PFTC), sponsored by Sanofi. Started Mar 2006; status: completed.
02
Drugs
docetaxeloxaliplatin
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube carcinoma (PFTC)
Beyond the preview
Go deeper on NCT00296816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00296816.